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Dear Editor: 
Neuro-Oncology recently published the first safety and efficacy data on a transforming 
growth factor (TGF)--inhibiting approach in a brain tumor trial.1 TGF- is a potent cytokine with 
multiple biological activities which has become an attractive target in glioblastoma2 because of 
its immunosuppressive properties3 and its role in angiogenesis, migration, and invasion.4,5 
Recently, TGF- was also implicated in the maintenance of the glioma-initiating cell pool.6 
Consequently, a TGF- inhibitory compound such as the antisense oligonucleotide trabedersen 
(AP 12009)7 may be expected to reduce angiogenesis, migration, and invasion and promote the 
activity of natural killer and cytotoxic T cells, resulting in benefits for the treated patient cohort. 
However, the AP 12009-G004 trial, which compared standard chemotherapy (temozolomide or 
procarbazine-lomustine-vincristine [PCV]) with 10 or 80 µM trabedersen in a cohort of 145 
patients with recurrent or refractory anaplastic astrocytoma or glioblastoma, was negative for 
the prespecified primary endpoint. That endpoint (documented at www.clinicaltrials.gov, 
accessed January 10, 2011) was defined as the cumulative rate of patients experiencing 
complete remission (CR), partial remission (PR), or stable disease (SD).8 Despite this overall 
negative result, the authors state in the ABSTRACT that trabedersen results in 3-fold survival at 
2 and 3 years compared with chemotherapy in a small subgroup of 9 versus 15 glioblastoma 
patients. We are concerned that a break-down of a study population into such small 
subpopulations creates a risk of overinterpretating apparent differences that may arisen by 
chance and are not supported by adequate biometrical analyses. 
First, the prestudy characteristics of the study groups differed. Five of the 28 
glioblastoma patients (17%) had not been treated with radiotherapy prior to study entry in the 
low- dose trabedersen arm. Given that this was a study with of “recurrent and /refractory” 
glioblastoma, one wonders what standard of care these patients been refractory to? Although 
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radiotherapy-naïve patients were also present in the other groups, at rates of 8%-10%, the 
differences between the groups in terms of previous treatment may have influenced the 
findings.  
Second, the reference chemotherapy arm is remarkable in that only 6 months of 
chemotherapy, likely corresponding to 6 cycles of temozolomide or 3 cycles of PCV, were 
planned. Was this considered “standard chemotherapy”? The median treatment duration for 
PCV was 29 (!) days, which corresponds to one 1 cycle. The contemporary British trial 
ISRCTN83176944, which evaluated temozolomide and PCV for recurrent high-grade glioma 
that progressed after radiotherapy, allowed a PCV treatment duration of 166 days,9 similar to 
the German NOA-04 trial with PCV at recurrence after radiotherapy in anaplastic glioma (152 
days),10 strongly suggesting that the reference arm patients received inadequate treatment.  
Third, the analysis of the trial is flawed in that outcome data are presented in a per 
protocol way declared here as the “primary efficacy population,” that is, the population of 
patients treated, not those intended to be treated. However, the rates of loss varied between the 
groups: 8 patients randomly assigned to trabedersen were excluded during the trial, compared 
with only 2 patients in the chemotherapy arm. The loss of these probably poor-prognosis 
patients likely had disproportionate effects in the low-dose trabedersen arm because this arm 
had the lowest total number of patients in its primary efficacy population. We worry that further 
clinical development of trabedersen might be built on the basis of the “superiority” of low- versus 
high-dose trabedersen in this comparison. Yet, an optimal dose cannot be derived from an 
inadequately powered comparison of two choices. 
Fourth, as noted above, the trial’s primary outcome measure was to be the overall 
response rate, or the percentage of patients CR, PR, or SD by Macdonald criteria.8 However, 
the primary endpoint reported was the “tumor control rate” at 6 months, which resembles the 
more commonly used concept of progression-free survival at 6 months. The reason for 
changing the original primary endpoint remains unclear, but should have been justified in the 
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publication. 
Fifth, almost all statements of significance or non-significance are related to comparisons of low 
numbers of cases; this is especially troubling given that anaplastic astrocytoma patients, which 
represented only 39 patients distributed among 3 study arms, are the basis for most of the 
reported conclusions. The profound prognostic heterogeneity of this patient population, on the 
basis of molecular markers including 1p/19q status, MGMT promoter methylation status, and 
IDH mutation status, is firmly established.10 Any imbalance in these factors could skew study 
results in various directions, but none of these factors was mentioned in the article. It was also 
not stated whether all patient specimens had undergone central pathologic analysis or whether 
the data were reported by local or central pathologists. Moreover, radiological assessment of 
response is now known to be a challenge,11 and there is no information about who assessed 
response in this trial. 
Sixth, the ad hoc and nonstandard definition of the concept PFS14 as an endpoint seems to 
suggest that other retrospectively crafted endpoints were also tested. The adoption of this 
measure is explained as reflecting an outcome for cases with “sufficient MRI data available for 
interpretable analysis,” but no real justification for needing such an analysis is provided. 
Furthermore, Table 2 in the article shows that in the small subgroup of anaplastic astrocytoma 
patients at 14 months, MRI scans were missing for 25% in the low-dose arm, 40% in the high-
dose arm, and 42% in the chemotherapy arm; this challenges the view that the MRI data were 
sufficient for analysis. 
Seventh, no information about salvage treatment by study arm was provided, preventing 
readers from being able to determine if the interpretation of the overall survival data was 
appropriate. 
Despite the disappointing outcome of this trial, we remain confident that TGF- is a 
relevant target in glioblastoma. Going forward, it will be important to subject data relating to 
trabedersen to central review and to investigate the extent to which the oligonucleotide inhibits 
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its target in vivo. It will be important to incorporate biological endpoints into future 
immunotherapy trials in glioblastoma. 
We concur with the notion that trabedersen did not produce unexpected or harmful 
toxicity.1 Trabedersen neutralizes only TGF-2, whereas TGF-1 or TGF-3 released by glioma 
or glioma-infiltrating (e.g., microglial) cells will at least not directly be affected. Despite persistent 
safety concerns,12 the future of anti-TGF- agents may be brighter for small molecule 
antagonists of the TGF- receptor, which have shown truly promising activity in relevant rodent 
glioma models.13,14  
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